COVID-19 and Vaccine-Induced Thrombosis.

Q3 Medicine
Tanaffos Pub Date : 2022-04-01
Babak Sharif-Kashani, Shadi Shafaghi, Farah Naghashzadeh, Abdolreza Mohamadnia, Mohammad Rahdar, Maryam Hajimoradi, Sima Noorali
{"title":"COVID-19 and Vaccine-Induced Thrombosis.","authors":"Babak Sharif-Kashani,&nbsp;Shadi Shafaghi,&nbsp;Farah Naghashzadeh,&nbsp;Abdolreza Mohamadnia,&nbsp;Mohammad Rahdar,&nbsp;Maryam Hajimoradi,&nbsp;Sima Noorali","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19), a highly contagious infectious disease, has had a catastrophic effect on the world's demographics resulting in more than 2.9 million deaths worldwide till January 2021. It can lead to systemic multi-organ complications; in particular, venous and arterial thromboembolism risk is significantly increased. Venous thromboembolism (VTE) occurs in 22.7% of patients with COVID-19 in the ICU and 8% in non-ICU hospitalized patients. Studies evaluating thromboprophylaxis strategies in patients with COVID-19 are needed to improve the prevention of VTE. VTE is the most commonly reported thrombotic complication, with higher incidence rates among critically ill patients. Several vaccines have been licensed and are currently used to combat the COVID-19 pandemic. Also, several cases of vaccine-induced thrombosis have been reported. Vaccination remains the most critical measure to curb the COVID-19 pandemic. There is a broad consensus that the benefits of vaccination greatly outweigh the potential risks of rare vaccine side effects, such as vaccine-induced immune thrombotic thrombocytopenia (VITT). Therefore, the importance of vaccination should be emphasized. This statement aims to focus on VITT.</p>","PeriodicalId":22247,"journal":{"name":"Tanaffos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/5e/Tanaffos-21-413.PMC10423859.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tanaffos","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Coronavirus disease 2019 (COVID-19), a highly contagious infectious disease, has had a catastrophic effect on the world's demographics resulting in more than 2.9 million deaths worldwide till January 2021. It can lead to systemic multi-organ complications; in particular, venous and arterial thromboembolism risk is significantly increased. Venous thromboembolism (VTE) occurs in 22.7% of patients with COVID-19 in the ICU and 8% in non-ICU hospitalized patients. Studies evaluating thromboprophylaxis strategies in patients with COVID-19 are needed to improve the prevention of VTE. VTE is the most commonly reported thrombotic complication, with higher incidence rates among critically ill patients. Several vaccines have been licensed and are currently used to combat the COVID-19 pandemic. Also, several cases of vaccine-induced thrombosis have been reported. Vaccination remains the most critical measure to curb the COVID-19 pandemic. There is a broad consensus that the benefits of vaccination greatly outweigh the potential risks of rare vaccine side effects, such as vaccine-induced immune thrombotic thrombocytopenia (VITT). Therefore, the importance of vaccination should be emphasized. This statement aims to focus on VITT.

COVID-19和疫苗诱发血栓。
2019冠状病毒病(COVID-19)是一种高度传染性疾病,对世界人口造成了灾难性影响,截至2021年1月,全球已有290多万人死亡。可导致全身性多器官并发症;特别是,静脉和动脉血栓栓塞的风险显着增加。22.7%的ICU患者和8%的非ICU住院患者发生静脉血栓栓塞(VTE)。需要对COVID-19患者的血栓预防策略进行评估,以改善静脉血栓栓塞的预防。静脉血栓栓塞是最常见的血栓性并发症,在危重患者中发病率较高。已有几种疫苗获得许可,目前用于对抗COVID-19大流行。此外,还报告了几例疫苗引起的血栓形成病例。疫苗接种仍然是遏制COVID-19大流行的最关键措施。广泛的共识是,疫苗接种的益处大大超过罕见疫苗副作用的潜在风险,例如疫苗诱导的免疫性血栓性血小板减少症(VITT)。因此,应强调疫苗接种的重要性。这一声明的重点是VITT。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Tanaffos
Tanaffos Medicine-Critical Care and Intensive Care Medicine
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信